Abstract
Background and Objective: Gold nanoparticles (AuNP) conjugated with either EpCAM or TARP antibodies and an anticancer agent, paclitaxel (PTX), for tumour targeting and therapy were synthesised using a simple chemistry.
Methods: The AuNP surface was functionalised using a two-step modification approach. The conjugates were characterised using Transmission Electron Microscopy (TEM) and infrared spectroscopy.
Results: The cytotoxicity assay of T47D cells treated with only antibodies conjugated to the gold nanoparticles did not show any cytotoxicity to the cells, which indicates these nanoconjugates are suitable for intracellular delivery of anticancer drugs.
Conclusion: When using AuNPs with antibodies and the cancer chemotherapy agent PTX attached simultaneously to the functionalised AuNPs, the reduction of cell viability was significantly higher compared to PTX-thiol-AuNPs conjugate system where no antibodies were used.
Keywords: Gold nanoparticles, paclitaxel, EpCAM, TARP, antibodies, cytotoxicity, drug delivery.
Drug Delivery Letters
Title:Specific Targeting of Breast Cancer Cells with Antibodies Conjugated Gold Nanoparticles
Volume: 8 Issue: 3
Author(s): Zahrah Alhalili, Joe Shapter*, Daniela Figueroa and Barbara Sanderson
Affiliation:
- Flinders Centre for NanoScale Science and Technology, School of Chemical and Physical Sciences, Flinders University, Adelaide, SA 5001,Australia
Keywords: Gold nanoparticles, paclitaxel, EpCAM, TARP, antibodies, cytotoxicity, drug delivery.
Abstract: Background and Objective: Gold nanoparticles (AuNP) conjugated with either EpCAM or TARP antibodies and an anticancer agent, paclitaxel (PTX), for tumour targeting and therapy were synthesised using a simple chemistry.
Methods: The AuNP surface was functionalised using a two-step modification approach. The conjugates were characterised using Transmission Electron Microscopy (TEM) and infrared spectroscopy.
Results: The cytotoxicity assay of T47D cells treated with only antibodies conjugated to the gold nanoparticles did not show any cytotoxicity to the cells, which indicates these nanoconjugates are suitable for intracellular delivery of anticancer drugs.
Conclusion: When using AuNPs with antibodies and the cancer chemotherapy agent PTX attached simultaneously to the functionalised AuNPs, the reduction of cell viability was significantly higher compared to PTX-thiol-AuNPs conjugate system where no antibodies were used.
Export Options
About this article
Cite this article as:
Alhalili Zahrah, Shapter Joe*, Figueroa Daniela and Sanderson Barbara, Specific Targeting of Breast Cancer Cells with Antibodies Conjugated Gold Nanoparticles, Drug Delivery Letters 2018; 8 (3) . https://dx.doi.org/10.2174/2210303108666180913115509
DOI https://dx.doi.org/10.2174/2210303108666180913115509 |
Print ISSN 2210-3031 |
Publisher Name Bentham Science Publisher |
Online ISSN 2210-304X |
Call for Papers in Thematic Issues
Nanomaterial Assisted Targeted Therapies for Chronic Disorders- Preclinical to Clinical Outcomes
In recent years, the integration of nanomaterials into therapeutic strategies has emerged as a promising avenue in the pursuit of more effective treatments for chronic disorders. This dynamic field, explored in the context of "Nanomaterial Assisted Targeted Therapies for Chronic Disorders - Preclinical to Clinical Outcomes," seeks to bridge the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anti-Angiogenic Agents and Cancer: Current Insights and Future Perspectives
Recent Patents on Anti-Cancer Drug Discovery Inhibition of Polo-Like Kinase 1 by BI2536 Reverses the Multidrug Resistance of Human Hepatoma Cells In Vitro and In Vivo
Anti-Cancer Agents in Medicinal Chemistry Green Synthesis of Metal Nanoparticles from Adiantum Frond: Comparative Analysis on Cancer Cell Lines
Nanoscience & Nanotechnology-Asia TRP Channels and Cancer: New Targets for Diagnosis and Chemotherapy
Endocrine, Metabolic & Immune Disorders - Drug Targets HOXB7 and Hsa-miR-222 as the Potential Therapeutic Candidates for Metastatic Colorectal Cancer
Recent Patents on Anti-Cancer Drug Discovery Disruption of Metabolic Pathways - Perspectives for the Treatment of Cancer
Current Cancer Drug Targets Meet Our Editorial Board Member:
Current Cancer Drug Targets Epidermal Growth Factor Receptor (EGFR) Targeted Therapies in Non- Small Cell Lung Cancer (NSCLC)
Reviews on Recent Clinical Trials METCAM/MUC18 Expression and Cancer Metastasis
Current Genomics Recent Patents on New Steroid Agents Targeting the Steroidogenesis for Endocrine Cancer Treatments
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Relevance of Nutritional Antioxidants in Metabolic Syndrome, Ageing and Cancer: Potential for Therapeutic Targeting
Infectious Disorders - Drug Targets Melanin Biosynthesis Inhibitors from Wood of Artocarpus heterophyllus: The Effect of Isoprenoid Substituent of Flavone with 4-Substituted Resorcinol Moiety at B Ring
Letters in Drug Design & Discovery The Nitric Oxide Prodrug JS-K and Its Structural Analogues as Cancer Therapeutic Agents
Anti-Cancer Agents in Medicinal Chemistry Genetics and Genomics of Hepatic Acute Phase Reactants: A Mini-Review
Inflammation & Allergy - Drug Targets (Discontinued) Impact of the Emulsification-Diffusion Method on the Development of Pharmaceutical Nanoparticles
Recent Patents on Drug Delivery & Formulation Expression Microarray Proteomics and the Search for Cancer Biomarkers
Current Genomics Non-Surgical Treatment Options for Symptomatic Uterine Leiomyomas
Current Women`s Health Reviews CDC25A: A Rebel Within the CDC25 Phosphatases Family?
Anti-Cancer Agents in Medicinal Chemistry Transglutaminase-Mediated Activation of Nuclear Transcription Factor-κB in Cancer Cells: A New Therapeutic Opportunity
Current Cancer Drug Targets Prolyl Oligopeptidase: A Rising Star on the Stage of Neuroinflammation Research
CNS & Neurological Disorders - Drug Targets